The product patents are “valid through 2032 and 2030, respectively,” Suven Life Sciences said in a filing to BSE.
With these new patents, the company has a total of 23 patents from Canada and 20 patents from Hong Kong, it added.
The new chemical entities (NCEs) are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer’s disease, Parkinson and Schizophrenia, Suven Life Sciences said.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Suven CEO Venkat Jasti said.
“The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents…,” Suven Life Sciences said.
Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, it added.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
